Skip to main content
. Author manuscript; available in PMC: 2010 Jan 1.
Published in final edited form as: Recent Pat Inflamm Allergy Drug Discov. 2009;3(2):96–112. doi: 10.2174/187221309788489779

Table 3.

The “dustpile of failed sepsis trials”

anti-TNF monoclonal antibody (MAb) clinical trials [203, 204]
 NORAEPT I
 NORASEPT II
 INTERSEPT
p55 tumor necrosis factor receptor fusion protein [102, 205–207]
Fc portion of IgG1 (TNFR:Fc) [205]
anti-TNF antibody fragment [208]
 MAK 195F
anti-endotoxin MAb clinical trials [24, 101, 209–217]
 HA-1A
 E5
recombinant human interleukin-1 receptor antagonist [103, 218]
NOS inhibitor 546C88 [219]
pentoxifylline [220]
Anti-thrombin III [221–228]
Tissue factor pathway inhibitor (TFPI) [229, 230]
platelet-activating factor acetylhydrolase (PAF-AH) [231, 232]
group IIA secretory phospholipase A [233]
Bactericidal/permeability-increasing protein (BPI) [25, 26]
Ibuprofen [234, 235]